- Current report filing (8-K)
December 03 2009 - 2:04PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of
The
Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported):
December 3, 2009
ALLOS
THERAPEUTICS, INC.
(Exact name of registrant
as specified in its charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State or other
jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
11080
CirclePoint Road, Suite 200
Westminster, Colorado
|
|
80020
|
(Address of principal
executive offices)
|
|
(Zip Code)
|
Registrants telephone
number, including area code:
(303) 426-6262
Not
applicable
(Former name or former
address, if changed since last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2.
below):
o
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 8
Other Events
Item
8.01
Other Events.
On December 3, 2009,
the Company issued a press release announcing the launch of COMPLETE (
C
omprehensive
O
ncology
M
easures for
P
eriphera
l
T-c
e
ll Lymphoma
T
r
e
atment), a global observational study designed to address the
urgent need to better understand treatment patterns and outcomes for patients
with peripheral T-cell lymphoma (PTCL).
The
press release is attached hereto as Exhibit 99.1 and incorporated herein
by reference.
Section 9
Financial Statements and Exhibits
Item
9.01
Financial Statements and
Exhibits.
(d)
Exhibits
99.1
Press
Release, dated December 3, 2009, entitled Allos Therapeutics to Launch Global Registry for Patients with Peripheral
T-Cell Lymphoma at the American Society of Hematology Annual Meeting.
2
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
Dated: December 3,
2009
|
|
ALLOS THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Marc H. Graboyes
|
|
|
Marc H. Graboyes
|
|
Its:
|
Senior Vice President,
General Counsel and Secretary
|
3
EXHIBIT
INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press
Release, dated December 3, 2009, entitled Allos Therapeutics to Launch Global Registry for Patients with
Peripheral T-Cell Lymphoma at the American Society of Hematology Annual
Meeting.
|
4
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024